Last update 29 Aug 2025

Pnb Vesper Life Science

Dissolved
| Private Company

Overview

Tags

Digestive System Disorders
Neoplasms
Other Diseases
Small molecule drug

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Nervous System Diseases3
Neoplasms3
Immune System Diseases1
Infectious Diseases1
Endocrinology and Metabolic Disease1
Top 5 Drug TypeCount
Small molecule drug6
Top 5 TargetCount
CCKA x CCKB3
CCK receptor(Cholecystokinin receptors)2
CCKA(Cholecystokinin A receptor)1

Related

6
Drugs associated with Pnb Vesper Life Science
PNB-001
Target
CCKA x CCKB
Mechanism
CCKA antagonists [+1]
Active Org.
Pnb Vesper Life Science
Originator Org.
Pnb Vesper Life Science
Active Indication
COVID-19 [+4]
Inactive Indication-
Drug Highest PhasePhase 3
First Approval Ctry. / Loc.-
First Approval Date-
PNB-028
Target
CCK receptor
Mechanism
CCK receptor antagonists
Active Org.
Pnb Vesper Life Science
 [+1]
Originator Org.
Pnb Vesper Life Science
Active Indication
Colonic Cancer [+1]
Inactive Indication-
Drug Highest PhasePhase 1/2
First Approval Ctry. / Loc.-
First Approval Date-
PNB-081
Target
CCKA
Mechanism
CCKA antagonists
Active Org.
Pnb Vesper Life Science
 [+1]
Originator Org.
Pnb Vesper Life Science
Active Indication
Opioid abuse [+2]
Inactive Indication-
Drug Highest PhaseIND Application
First Approval Ctry. / Loc.-
First Approval Date-
6
Clinical Trials associated with Pnb Vesper Life Science
CTRI/2024/01/062125
/ Not yet recruitingPhase 1
A single arm, open label, multiple ascending dose, prospective, multicentre study to assess safety, tolerability, pharmacokinetics and pharmacodynamic of PNB028 (Test, manufactured by PNB Vesper Life Science Pvt. Ltd., India) in colon or pancreatic cancer patients.
CTRI/2022/10/046658
/ RecruitingPhase 2
A Phase II, Multicenter, Randomized, Double-blind, Placebo controlled Clinical study toevaluate efficacy and safety of PNB-001 as an adjunct to Mesalamine compared toMesalamine alone in Subjects with Inflammatory bowel disease
CTRI/2021/09/036411
/ RecruitingPhase 3
A Phase III, Randomized, Open Label, Multicentric, Clinical Study to Evaluate the Efficacy and Safety of PNB-001 as an Adjunct to Standard of Care Compared to Standard of Care Alone in Treatment of Patients with Moderate COVID-19 Infection
100 Clinical Results associated with Pnb Vesper Life Science
Login to view more data
0 Patents (Medical) associated with Pnb Vesper Life Science
Login to view more data
100 Deals associated with Pnb Vesper Life Science
Login to view more data
100 Translational Medicine associated with Pnb Vesper Life Science
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 03 Sep 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Preclinical
3
1
IND Application
Phase 2
1
1
Phase 3
Other
1
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
PNB-001
 ( CCKA x CCKB )		Crohn Disease
More
Phase 2
PNB-028
 ( CCK receptor )		Colonic Cancer
More
Phase 1/2
PNB-081
 ( CCKA )		Pain
More
Preclinical
PNB-291
 ( CCKA x CCKB )		Brain Cancer
More
Preclinical
PNB-101
 ( CCK receptor )		Small Cell Lung Cancer
More
Preclinical
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free